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Key Clinical Message
Maternal cell-free DNA (cfDNA) results that are discordant with the diagnostic
fetal karyotype should prompt further investigation. If deeper analysis of the
cfDNA results demonstrates a “saw-tooth” pattern characteristic of genome-
wide imbalance, maternal malignancy is suggested. Identifying the maternal
malignancy can, however, be difficult.
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Introduction
Maternal plasma cell-free DNA (cfDNA) analysis has
become a preferred method chosen by patients to screen
for common fetal trisomies. However, when the results
are discordant with follow-up diagnostic testing, there are
limited follow-up recommendations at present for practi-
tioners and patients. Possible explanations for discordant
results include confined placental mosaicism, maternal
chromosomal mosaicism, co-twin demise, DNA copy
number variants in mother or fetus, maternal organ
transplant from a male donor, and maternal malignancy
[1]. Here, we report a patient who had plasma cfDNA
test results suggestive of full or partial monosomies for
chromosomes 13, 18, 21, and X who was subsequently
found to have hepatic lesions on magnetic resonance
imaging (MRI). Postpartum the patient was diagnosed
with stage IV colon cancer.
Case History
The patient was a 37-year-old G2P1001 woman who
2 years earlier had undergone in vitro fertilization and
preimplantation genetic testing for cystic fibrosis as both
she and her husband are carriers. This resulted in a full
term, healthy female. During this first pregnancy, the
patient had plasma cfDNA testing in that pregnancy that
was reported as low risk for fetal aneuploidy.
In the current pregnancy, the couple used their remain-
ing frozen embryos to conceive. Two embryos were trans-
ferred. A subsequent ultrasound scan demonstrated a
single, viable intrauterine pregnancy. Maternal plasma
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cfDNA test results at 12 weeks suggested full or partial
monosomies for chromosomes 13, 18, 21, and X. The
patient then underwent diagnostic testing by amniocente-
sis at 18 weeks’ gestation. The fetus had a 46, XX kary-
otype and a normal chromosomal microarray.
The concern for a maternal malignancy as an explana-
tion for the discordant results between the cfDNA study
and amniocentesis prompted a request for a deeper analy-
sis of the whole-genome sequencing results by the original
testing laboratory (Fig. 1). This showed multiple areas of
genome-wide imbalance, suggestive of malignancy. The
patient was subsequently referred to the cancer genetic
counseling service for an oncologic evaluation at 21-
weeks’ gestation. She was clinically asymptomatic. Her
general physical examination was normal, and laboratory
studies were unremarkable. Her family history was not
suggestive of a hereditary cancer syndrome.
Following a discussion with multiple medical special-
ists, a full body MRI scan without contrast was performed
at 23 weeks’ gestation to search for a possible malignancy
(Fig. 2). The imaging identified multiple T2 hyperintense
and T1 hypointense lesions in the liver: the largest mea-
sured 5.5 9 4.3 9 6.6 cm. The differential diagnosis
included hepatic adenomas, primary hepatocellular carci-
noma, or metastatic lesions. The patient was further
counseled regarding these new findings. The decision was
made not to perform a liver biopsy.
The patient underwent another MRI scan at 27 weeks’
gestation. This demonstrated that the hepatic lesions had
increased in size with the largest one measuring
9.9 9 5.4 9 8.8 cm. Due to the concern that the lesions
could become hemorrhagic, at 28 weeks’ gestation the
patient underwent an invasive radiology-guided emboliza-
tion procedure. A repeat maternal plasma cfDNA
analysis continued to show multiple monosomies.
Evaluation of the whole-genome sequencing results
showed a similar but more exaggerated pattern of gen-
ome-wide imbalance compared to the previous test
(Fig. 1). Because of a dropping hematocrit and increas-
ing right upper quadrant pain, a third MRI scan was
performed, which demonstrated that the largest lesion
measured 10.5 9 5.4 9 9.7 cm and the smaller lesions
were reduced in size. Her liver enzyme values remained
normal.
The patient underwent a planned cesarean delivery at
32-weeks’ gestation to facilitate her medical management.
At the time of her surgery, fine needle biopsies of four
liver lesions were performed. Three lesions demonstrated
necrotic type material consistent with the patient’s recent
Figure 1. Genome-wide data from NIPS performed at 12 weeks (green line) and then repeated early third trimester (blue line). Multiple copy
number variants are seen across the genome leading to the saw-tooth pattern seen above, with increasing copy numbers of mapped sequences
in the repeat sample. Both test results reported full or partial monosomy for chromosomes 13, 18, 21, and X, which was the result of the excess
amounts of DNA sequences in chromosomes 7, 8, 10, 14, and 20 causing the bioinformatics algorithm to interpret the abnormal ratios as
monosomies of the test chromosomes.
Figure 2. Abdominal MRI at 23-weeks’ gestation identified multiple
T2 hyperintense and T1 hypointense lesions in the liver.
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embolization. One biopsy demonstrated poorly differenti-
ated adenocarcinoma. Postpartum, she had a CT scan
that demonstrated cecal thickening. Subsequent colono-
scopy revealed a circumferential mass involving the cecum
and proximal ascending colon. Multiple biopsies were
taken but did not reveal any evidence of malignancy. The
patient underwent a positron emission tomography (PET)
scan that demonstrated a fluorodeoxyglucose(FDG)-avid
cecal mass consistent with colon cancer along with FDG-
avid pericecal lymph nodes consistent with metastasis. In
addition, there were FDG-avid right lobe hepatic lesions,
which were consistent with metastases. The patient had a
repeat biopsy of the hepatic lesion that demonstrated
metastatic poorly differentiated adenocarcinoma. The
diagnosis was stage IV colon cancer, and systemic
chemotherapy was initiated. There was no response, so
she underwent a right colectomy and partial hepatectomy.
She then had a second round of chemotherapy but did
not respond and died approximately 10-months postpar-
tum. The infant is alive and well.
Given the abnormal cfDNA test results seen in the sec-
ond pregnancy, the genome-wide tracings from the first
pregnancy were retrospectively reviewed and were still
considered to be unremarkable.
Discussion
Fetal cfDNA is detectable in maternal serum as early as
5–7 weeks of gestation [2]. In the first trimester, approxi-
mately 10% of cfDNA is fetal in origin and is almost
entirely derived from placental trophoblast cells. Several
different techniques exist to analyze cfDNA [2]. The tech-
nique used to analyze the DNA in the patient’s sample
was massively parallel shotgun sequencing (MPSS). MPSS
involves identifying and counting DNA fragments. Both
maternal and fetal DNA segments are sequenced simulta-
neously. The segments are sequenced, aligned, and
uniquely mapped to sites from a reference human gen-
ome. Each individual laboratory employs its own statisti-
cal method to determine when to call a sample
monosomic or trisomic for a specific chromosome. The
test utilized here incorporated a software program called
bowtie to align the sequences to the 19th reference ver-
sion of the human genome sequence map [3]. The clinical
laboratory’s proprietary software then evaluated the target
chromosomes (13, 18, 21, X, and Y) by calculating a ratio
between the normalized coverage on each target chromo-
some to the sum of normalized coverage on a respective
set of reference chromosomes (typically two to six chro-
mosomes). The software has upper and lower limits that
it applies to the test results in order to generate an aneu-
ploidy classification status for chromosomes 13, 18, and
21. These include aneuploidy detected, suspected, or no
aneuploidy. For sex chromosomes it includes aneuploidy
detected or not. The excess amount of circulating DNA
sequences from the reference chromosomes, particularly
the chromosomes with peak sequences above the horizon-
tal line in Figure 1, resulted in abnormal ratios, thus gen-
erating the test results of monosomies for 13, 18, 21, and
X. The screening result of multiple monosomies is caused
by a bioinformatics artifact.
Because the patient’s sample was analyzed by MPSS,
the genome-wide data were available and could be re-
analyzed. These demonstrated an abnormal pattern of
multiple chromosomes across the genome that led to a
“saw-tooth” pattern (Fig. 1). Given the multiple abnormal-
ities across the genome, this pattern was suspicious for a
malignancy. However, genome-wide aberrations have also
been reported for benign, neoplastic lesions in pregnancy,
such as uterine leiomyomas [4]. If the patient’s sample had
been tested using the targeted sequencing method that does
not use ratios, the results from chromosomes 13, 18, and
21 would likely have been normal and the suspicion for
cancer may not have been raised.
CfDNA levels are frequently elevated in patients with
cancer [5–8]. Ongoing research is addressing whether the
increased cfDNA levels can be used for different purposes
in cancer screening and monitoring response to treatment
[6]. Several studies have demonstrated that plasma cfDNA
is increased in metastatic colon cancer [8]. Other, nonra-
tio approaches use detection and monitoring of a tumor-
specific oncogene such as KRAS. This was not done here,
and in fact, would require a separate test from the MPSS
counting approach.
In 2013, the first case of a pregnant patient with
discordant results subsequently being diagnosed with
metastatic cancer was published [5]. The patient was a
37-year-old G2P1 woman with cfDNA test results that
demonstrated fetal aneuploidy for chromosomes 13 and
18. At two-week postpartum, the patient was diagnosed
with metastatic small cell carcinoma of vaginal origin. In
June 2015, three more patients diagnosed with cancer
(ovarian carcinoma, follicular lymphoma, and Hodgkin
lymphoma) after discordant cfDNA results were reported
[6]. In July 2015, an additional ten pregnant patients were
reported to have a malignancy after undergoing cfDNA
testing (neuroendocrine of unknown origin, non-Hodgkin
lymphoma in three patients, colorectal, Hodgkin lym-
phoma, acute T-cell lymphoblastic leukemia, and two
patients critically ill with type of cancer not reported) [7].
Conclusion
Management of the pregnant woman with discordant
cfDNA results remains a clinical dilemma, particularly
when genome-wide sequencing results suggest
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malignancy. The most common cancers that have been
diagnosed in pregnant patients include breast, cervical,
Hodgkin lymphoma, leukemias, and malignant mela-
noma. These are also the most common types of cancers
seen in women of reproductive age [9]. As more informa-
tion becomes available, specific cfDNA test result patterns
may be helpful in guiding the subsequent evaluation. The
extent of the diagnostic work up may be limited by the
pregnancy itself. Standard serologic tumor markers are
unreliable in a pregnant woman.
The current recommendations for evaluation of malig-
nancy in the setting of discordant cfDNA results are only
based on expert opinions; these include obtaining a com-
plete blood count, chemistry panel, whole-body MRI scan
without contrast [6], and referral to medical oncology.
Similarly for women who are not pregnant, for whom there
is a suspicion of malignancy, there are no standard evalua-
tions for cancer of unknown primary cell type [10].
Patients diagnosed with cancer typically present with signs
or symptoms that together with focused diagnostic testing
lead to an eventual diagnosis. Most of the pregnant women
identified to date because of abnormal cfDNA test results
have been initially asymptomatic. A systematic multidisci-
plinary approach to cataloging additional cases of discor-
dant cfDNA results, and their associated diagnoses, is
needed in order to better define patient-specific risks and
consistent recommendations for diagnosis and treatment.
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